Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 64

    Bayer Roundup suits increase to 42700

    Bayer Roundup suits increase to 42700

    Medical Dialogues Bureau1 Nov 2019 9:00 AM IST
    A court-appointed mediator between Bayer and US plaintiffs in August denied reports the company had offered an $8 billion settlement to get the cases...
    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Farhat Nasim31 Oct 2019 3:27 PM IST
    In 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
    JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

    JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

    Farhat Nasim31 Oct 2019 12:39 PM IST
    Hyderabad: Johnson & Johnson(JnJ) recently announced the expansion of its tuberculosis (TB) program in India in advance of the 50th Union World...
    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    Medical Dialogues Bureau31 Oct 2019 9:45 AM IST
    Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
    Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

    Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

    Medical Dialogues Bureau31 Oct 2019 9:25 AM IST
    The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous...
    GSK lifts annual profit forecast after third quarter beat on vaccines strength

    GSK lifts annual profit forecast after third quarter beat on vaccines strength

    Medical Dialogues Bureau31 Oct 2019 9:00 AM IST
    GSK now expects full-year profit to be roughly flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.New...
    IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

    IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

    Medical Dialogues Bureau30 Oct 2019 2:11 PM IST
    Mumbai: IOL Chemicals and Pharmaceuticals (IOLCP) recently received a communication from US Food and Drug Administration (USFDA) with respect to an...
    New tests shows NO sign of asbestos in recalled JnJ baby powder

    New tests shows NO sign of asbestos in recalled JnJ baby powder

    Medical Dialogues Bureau30 Oct 2019 1:18 PM IST
    But Johnson & Johnson (JnJ) said in a statement that dozens of tests by two outside firms did not detect any asbestos in JnJ's baby powder.New...
    Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates

    Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates

    Medical Dialogues Bureau30 Oct 2019 9:30 AM IST
    Pfizer said it expects to earn between $2.94 per share and $3.00 per share, up from a prior estimate of $2.76 to $2.86. Analysts on average were...
    Amgen Repatha to be available exclusively at 60 pc lower price in 2020

    Amgen Repatha to be available exclusively at 60 pc lower price in 2020

    Medical Dialogues Bureau30 Oct 2019 9:15 AM IST
    New Delhi: Amgen recently announced that effective Dec. 31, 2019, Repatha (evolocumab), an innovative treatment for patients with high cholesterol and...
    Jubilant Life Sciences appoints Alok Vaish as CFO, Key Managerial Personnel

    Jubilant Life Sciences appoints Alok Vaish as CFO, Key Managerial Personnel

    Medical Dialogues Bureau30 Oct 2019 9:00 AM IST
    New Delhi: Jubilant Life Sciences has recently announced its board has approved the appointment of Alok Vaish as Chief Financial Officer and Key...
    Biocon bags sixth place in Global Biotech Employers ranking for 2019

    Biocon bags sixth place in Global Biotech Employers ranking for 2019

    Farhat Nasim29 Oct 2019 11:30 AM IST
    Kiran Mazumdar Shaw, CMD, Biocon said: "We have consciously created a culture that encourages ideation, experimentation and collaboration to address...
    PrevNext

    Popular Stories

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Why Family Health Insurance Plan needs a Timely Re-Evaluation?

    Why Family Health Insurance Plan needs a Timely Re-Evaluation?

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Health Insurance- The Best Backup Plan in Today

    Health Insurance- The Best Backup Plan in Today's Times

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok